SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results